E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings

The nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV) has been co-formulated with emtricitabine and tenofovir disoproxil fumarate for initial therapy of HIV-1-infected individuals. RPV, formulated as a long-acting nanosuspension, will also be assessed for its ability to prevent HI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sluis-Cremer, Nicolas, Jordan, Michael R., Huber, Kelly, Wallis, Carole L., Bertagnolio, Silvia, Mellors, John W., Parkin, Neil T., Harrigan, P. Richard
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4089891/
https://ncbi.nlm.nih.gov/pubmed/24746459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2014.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados